JP2017508475A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508475A5
JP2017508475A5 JP2016559286A JP2016559286A JP2017508475A5 JP 2017508475 A5 JP2017508475 A5 JP 2017508475A5 JP 2016559286 A JP2016559286 A JP 2016559286A JP 2016559286 A JP2016559286 A JP 2016559286A JP 2017508475 A5 JP2017508475 A5 JP 2017508475A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antigen
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559286A
Other languages
English (en)
Japanese (ja)
Other versions
JP6865585B2 (ja
JP2017508475A (ja
Filing date
Publication date
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Application filed filed Critical
Priority claimed from PCT/EP2015/056654 external-priority patent/WO2015144855A1/en
Publication of JP2017508475A publication Critical patent/JP2017508475A/ja
Publication of JP2017508475A5 publication Critical patent/JP2017508475A5/ja
Priority to JP2021064572A priority Critical patent/JP7607498B2/ja
Application granted granted Critical
Publication of JP6865585B2 publication Critical patent/JP6865585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559286A 2014-03-26 2015-03-26 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 Active JP6865585B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021064572A JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1405477.9 2014-03-26
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
GB1405475.3 2014-03-26
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064572A Division JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Publications (3)

Publication Number Publication Date
JP2017508475A JP2017508475A (ja) 2017-03-30
JP2017508475A5 true JP2017508475A5 (enExample) 2018-05-17
JP6865585B2 JP6865585B2 (ja) 2021-04-28

Family

ID=52745885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016559286A Active JP6865585B2 (ja) 2014-03-26 2015-03-26 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Country Status (22)

Country Link
US (6) US20170204174A1 (enExample)
EP (3) EP3122775B1 (enExample)
JP (3) JP6865585B2 (enExample)
KR (1) KR102520978B1 (enExample)
CN (1) CN106536553B (enExample)
AU (2) AU2015238264B2 (enExample)
BR (1) BR122023027559A2 (enExample)
CY (1) CY1122456T1 (enExample)
DK (2) DK3122775T3 (enExample)
ES (2) ES2763859T3 (enExample)
FI (1) FI3653644T3 (enExample)
HR (2) HRP20231514T1 (enExample)
HU (2) HUE064573T2 (enExample)
IL (2) IL248038B (enExample)
LT (2) LT3122775T (enExample)
NZ (1) NZ724649A (enExample)
PL (2) PL3122775T3 (enExample)
PT (2) PT3653644T (enExample)
RS (1) RS59700B1 (enExample)
SI (1) SI3122775T1 (enExample)
SM (1) SMT202000064T1 (enExample)
WO (1) WO2015144855A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
EP3851122A1 (en) 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3356827B1 (en) 2015-10-02 2023-12-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
KR102722730B1 (ko) * 2015-10-02 2024-10-25 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
JP7138567B2 (ja) * 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
MX389765B (es) * 2016-07-06 2025-03-20 Nat Res Council Canada Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
WO2018071493A1 (en) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
EP3551214B1 (en) * 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法
LT4243928T (lt) * 2020-11-10 2026-06-10 Catalym Gmbh Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui
WO2022207846A1 (en) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
IL310535A (en) * 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
CA3250445A1 (en) * 2022-01-26 2025-03-10 Yunnan Baiyao Group Co., Ltd. ANTIBODY MOLECULE DIRECTED AGAINST DIFFERENTIATION AND GROWTH FACTOR 15 AND ITS USE
EP4524158A4 (en) 2022-05-09 2025-12-17 Staidson Beijing Biopharmaceuticals Co Ltd Antibody that specifically recognizes gdf15 and use thereof
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
WO2025223473A1 (zh) * 2024-04-23 2025-10-30 劲方医药科技(上海)股份有限公司 抗gdf-15抗体及其应用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
CA2372119A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
ES2689328T3 (es) * 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
DK2441466T3 (da) * 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh) * 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
AU2013322628B2 (en) * 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
ES3066738T3 (en) * 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro

Similar Documents

Publication Publication Date Title
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
NZ740686A (en) Therapeutic cd47 antibodies
EA201791270A1 (ru) Модифицированные april-связывающие антитела
MX2024005027A (es) Anticuerpos de union a cd3.
NZ610734A (en) Human antibodies to the glucagon receptor
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PH12018502623B1 (en) Anti-pd-l1 antibodies and uses thereof
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
MX392340B (es) Anticuerpo anti cd73 humana.
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
EA201792221A1 (ru) Антитела против сортилина и способы их применения
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
RU2016100892A (ru) Антитела против tweakr и их применение
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
UA115781C2 (uk) Cx3cr1-зв'язуючий поліпептид
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
RU2017113732A (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)